This article by James Wilton first appeared on the CATIE website here.
Une version française est disponible ici.
The sexual transmission of HIV occurs after an exposure to fluids that contain HIV, such as semen and fluids from the vagina and rectum. The amount of virus in these fluids (also known as viral load) is the most important factor that determines whether an exposure to HIV will lead to infection. Research shows that a higher viral load increases the risk of HIV transmission and that a lower viral load decreases the risk.
The viral load in the blood of a person living with HIV is measured regularly to monitor the success of antiretroviral therapy (also called ART). Successful ART can reduce the viral load in the blood and other bodily fluids to undetectable levels, which can reduce the risk of sexual transmission. ART therefore represents an important new HIV prevention tool, which also has the potential to reduce the guilt, blame and anxiety associated with the possibility of transmitting HIV to a partner.
Several studies released over the past few years have confirmed that ART has HIV prevention benefits. The most well-known study is the randomized-controlled clinical trial known as HPTN 052. In this study, early initiation of ART reduced the risk of HIV transmission by 96% among heterosexual serodiscordant couples. However, the couples who participated in this study reported having mostly vaginal sex, so the reduction in HIV risk for anal sex remained unclear.
While HPTN 052 showed that ART can dramatically reduce the risk of HIV transmission through vaginal sex, the actual risk of HIV transmission (i.e., what the risk is lowered to) when the blood viral load is undetectable remained unknown, particularly for condomless sex.
Fortunately, two ongoing studies are investigating these unanswered questions. The studies are aiming to determine the actual risk of HIV transmission (for condomless vaginal and anal sex) when the HIV-positive partner’s blood viral load is undetectable. Preliminary results from one of these studies—the PARTNER Study—were released at the recent Conference on Retroviruses and Opportunistic Infections (CROI) held in Boston in March 2014. These results are the first to provide direct evidence that ART can reduce the risk of HIV transmission during anal sex.
The PARTNER study is a large observational study that is following serodiscordant couples at over 70 HIV clinics in 14 European countries. All of the couples enrolled:
The study began in September 2010 and is ongoing.
Once enrolled, the HIV-positive partner must commit to receiving their HIV care from the study clinic and both partners are required to attend the clinic every six months. At each visit, the HIV-positive partner’s viral load is measured, the HIV-negative partner’s HIV status is checked, and both partners are asked to complete a questionnaire about their sexual behaviour in the past six months. The HIV-positive partner also receives additional care, such as STI testing and information on the importance of adherence to ART, and both partners are told about the importance of using condoms to reduce the risk of HIV transmission.
If an HIV-negative partner becomes infected with HIV, a genetic analysis of the virus is performed. This is done to confirm that the virus was transmitted by the HIV-positive partner enrolled in the study and not by someone else outside of the relationship.
The preliminary results presented at CROI are part of a planned interim analysis. They are based on information from couples, followed up until November 2013, that met the following criteria:
Of the 1,110 couples recruited by November 2013, 767 met the above criteria. This included 282 same-sex male couples, 245 heterosexual couples where the HIV-positive partner was female, and 240 heterosexual couples where the HIV-positive partner was male. Overall, couples contributed a total of 894 couple-years of follow-up (equivalent to following 894 couples for a year).
At the start of the study, the HIV-positive partners had been on ART for an average of 5 years and couples had been having condomless sex for an average of 2 years.
During the preliminary study period, eligible couples reported condomless sex an average of 45 times a year (approximately once a week). This ranged from 16 times a year to 90 times a year. Same-sex male couples had sex more often than heterosexual couples. Same-sex male couples were also more likely to have a partner outside of the relationship (34% vs. 3% for heterosexual couples) and have a sexually transmitted infection (16% vs. 5%).
Between September 2010 and November 2013, the couples reported more than 44,000 condomless sex acts. These included:
Despite the large number of condomless sex acts, no HIV transmissions occurred between any of the couples enrolled in the study. However, some of the HIV-negative partners did become infected with HIV by a person outside of the relationship.
Since there was no control group in the PARTNER trial, it is difficult to know how many HIV transmissions would have occurred if the HIV-positive partner was not on ART and did not have an undetectable viral load. However, using information from previous studies, researchers estimated that 15 HIV infections in heterosexual couples and 86 among same-sex male couples would have occurred if the HIV-positive partner had not been on ART.
The PARTNER study represents the first direct evidence that ART can reduce the risk of HIV transmission for same-sex male couples.
Understanding and measuring certainty
The fact that no transmissions occurred in this study is very encouraging. However, as with any research finding, it is important to consider the role that chance may have played. This is particularly important when investigating HIV transmission risk, because the average risk of HIV infection can be relatively low in some cases, regardless of viral load. The lower the risk, the more difficult it is to measure accurately. In general, the larger the study, the more confident researchers can be that the results are real and did not occur due to chance.
One way of measuring certainty is to use confidence limits. Confidence limits take into account the potential effects of chance and suggest a range of values that likely encompass the “true” risk. In the PARTNER study, investigators calculated upper confidence limits for the risk of HIV transmission per sex act and over time. The “upper confidence limit” provides an estimate of the highest possible transmission risk that is consistent with the study results.
For this study, upper confidence limits can be interpreted as follows:
The upper confidence limit is particularly important when a study finds zero risk because it gives some indication of how close to zero the “true” risk is likely to be.
Risk per-act of sex
Upper confidence limits were calculated for the risk of HIV transmission per act of condomless sex with an HIV-positive partner:
For example, the upper confidence limit for receptive anal sex can be interpreted as follows:
Given the number of receptive anal sex acts that occurred and the fact that no HIV infections were observed, it is extremely likely that the “true” risk is somewhere between 0% and 0.05%, and extremely unlikely that it is above 0.05%. Although it is still possible that the “true” risk is zero, or only slightly higher than zero, the researchers could not rule out the possibility that the risk is as high as 0.05%.
Despite this uncertainty, this research is still meaningful. Many of the upper confidence limits are lower than the HIV transmission risks that have been estimated for when a person’s viral load is detectable. For example, the average per-act transmission risk for receptive anal sex has been estimated to be 1.4% when the viral load is detectable. However, the PARTNER study found that this risk is extremely likely to be below 0.05% when the viral load is undetectable.
Previous studies have estimated the average risk per condomless sex act when the viral load is detectable to be 0.08% for receptive vaginal sex, 0.04% for insertive vaginal sex and 0.06-0.62% for insertive anal sex. Therefore the PARTNER study strongly suggests that ART reduced the risk of HIV transmission for all types of sex.
Risk over time
Upper confidence limits were also calculated for a couple’s 10-year risk of HIV transmission when the HIV-positive partner has an undetectable viral load:
For example, the upper confidence limit for receptive anal sex can be interpreted as follows:
Given that couples were having condomless sex about once a week, it is extremely likely that the 10-year risk of HIV transmission is somewhere between 0 and 17.9% for receptive anal sex. While it is still possible that the “true” risk is zero, or only slightly higher than zero, the study could not rule out the possibility that the risk is as high as 17.9%.
It is important to note that the size of the upper confidence limit reflects the effects of chance. Receptive anal sex has the highest upper confidence limits because there were fewer receptive anal sex acts during the study compared to other types of sex. The lower number of sex acts means chance may have played a greater role.
The preliminary results from the PARTNER study provide important and encouraging new insight into the risk of transmitting HIV sexually when a person’s viral load is undetectable and no condom is used. These results can help serodiscordant couples assess their HIV risk and make informed decisions.
The investigators of the PARTNER study concluded that the overall risk of HIV transmission through condomless sex for couples in stable serodiscordant relationships (when the HIV-positive partner is on ART, receives regular HIV care, and has an undetectable blood viral load) is “extremely low, but uncertainty over the risk remains, particularly over receptive anal sex. Additional follow-up in MSM (men who have sex with men) is essential to provide more precise estimates for transmission risk given the current assumptions of safety in some communities.”
As the PARTNER study continues to follow couples who continue to have sex, the upper confidence limits will become “tighter” and move closer to zero—assuming that no HIV transmissions occur. This will allow the investigators to more confidently conclude that the risk of HIV transmission is “extremely low” for all types of vaginal and anal sex. The PARTNER study will continue to follow heterosexual couples until April 2014. Same-sex male couples will be followed until 2017 and the investigators plan to enroll 450 more gay male couples.
HPTN 052: The trial that changed everything – TreatmentUpdate
Treatment and viral load: what do we know about their effect on HIV transmission? – Prevention in Focus.
Putting a number on it: the risk from an exposure to HIV – Prevention in Focus
1. Baeten JM, Kahle E, Lingappa JR et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Science Translational Medicine. 2011 Apr 6;3(77):77ra29.
2. Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine. 2011 Aug 11;365(6):493–505.
3. Loutfy MR, Wu W, Letchumanan M et al. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS One. 2013;8(2):e55747.
4. Rodger A et al. HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study. In: Program and abstracts of the 21st Conference on Retroviruses and Opportunistic Infections, March 3 to 6th, 2014, Boston, U.S., abstract 153LB.
5. Baggaley RF, White RG, Boily M-C. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. International Journal of Epidemiology. 2010 Aug;39(4):1048–63.
6. Boily M-C, Baggaley RF, Wang L et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infectious Diseases. 2009 Feb;9(2):118–29.
7. Jin F, Jansson J, Law M et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS. 2010 Mar 27;24(6):907–13.
8. Wilson DP, Law MG, Grulich AE et al. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet. 2008 Jul 26;372(9635):314-20.
9. Wilson DP, Law MG, Gruclich AE et al. HIV transmission under highly active antiretroviral therapy. Lancet. 2008 Nov 22;372(9652):1807
CATIE is Canada’s source for up-to-date, unbiased information about HIV and hepatitis C. We connect people living with HIV or hepatitis C, at-risk communities, healthcare providers and community organizations with the knowledge, resources and expertise to reduce transmission and improve quality of life. For more details, please visit www.catie.ca or call 1-800-263-1638.
CATIE est la source d’information à jour et impartiale sur le VIH et l’hépatite C au Canada. Notre but est de partager les connaissances, les ressources et l’expertise avec les personnes vivant avec le VIH ou l’hépatite C, les communautés à risque, les fournisseurs de soins de santé et les organismes communautaires afin de diminuer la transmission des virus et d’améliorer la qualité de vie. Pour plus de renseignements, veuillez consulter www.catie.ca ou appelez le 1.800.263.1638.
Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV-related illness and the treatments in question. CATIE’s full disclaimer
Toute décision concernant un traitement médical particulier devrait toujours se prendre en consultation avec un professionnel ou une professionnelle de la santé qualifié(e) qui a une expérience des maladies liées au VIH et des traitements en question. Déni de responsabilité de CATIE